Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

Rhea-AI Summary

Zevra Therapeutics (Nasdaq: ZVRA) reported positive data for MIPLYFFA (arimoclomol) from a phase 2/3 open-label pediatric substudy in infants with Niemann-Pick disease type C.

The 5‑patient study (ages 12–<24 months) found arimoclomol, added to miglustat, was generally well tolerated with no new safety signals and pharmacokinetics consistent with older pediatric groups.

Positive

• Phase 2/3 pediatric substudy in 5 NPC infants completed up to 36 months
• Arimoclomol generally well tolerated with no new safety signals reported
• Pharmacokinetic profile consistent with older pediatric Niemann-Pick C populations
• Preliminary evidence supports initiating MIPLYFFA treatment in infants 12–<24 months
• Peer-reviewed publication strengthens clinical evidence base for MIPLYFFA in NPC

Negative

• Substudy enrolled only 5 infants, limiting statistical strength of findings
• Open-label design and heterogenous developmental delays constrain interpretability of efficacy

News Market Reaction – ZVRA

+2.77%

+2.77% Session close to close

In the Jun 23 session, ZVRA gained 2.77%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands MIPLYFFA’s clinical evidence with infant NPC data across up to 36 months o...

Analysis

This announcement expands MIPLYFFA’s clinical evidence with infant NPC data across up to 36 months of treatment. Prior news has produced mixed stock reactions; ongoing regulatory timelines and the company’s elevated short positioning remain key risk and watch points.

Key Figures

Pediatric sample size: 5 children Age at enrollment: 12 to <24 months Treatment duration: up to 36 months +1 more

4 metrics

Pediatric sample size 5 children NPC pediatric substudy with arimoclomol plus miglustat

Age at enrollment 12 to <24 months Infants with Niemann-Pick disease type C at study entry

Treatment duration up to 36 months Follow-up period assessing safety, tolerability, pharmacokinetics

Trial phase phase 2/3 Open-label pediatric substudy of arimoclomol in NPC

Historical Context

5 past events · Latest: Jun 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 11	Executive transition	Negative	-3.9%	CMO announced plans to step down with a transition and consulting period.
Jun 08	IP / patent update	Positive	+12.5%	New Orange Book patent listing aimed at strengthening MIPLYFFA market exclusivity.
May 29	Equity compensation	Neutral	-0.9%	Stock option inducement grants to new employees under Nasdaq listing rule.
May 12	Investor conference	Neutral	+2.3%	Announcement of participation and presentation at a BioConnect investor conference.
May 06	Earnings & update	Positive	-2.2%	Strong Q1 revenue growth, portfolio sale, debt prepayment, and pipeline progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows a mixed pattern, with some positive catalysts followed by negative price reactions, suggesting inconsistent alignment between headlines and short-term moves.

Key Terms

niemann-pick disease type c, pharmacokinetics, open-label, phenotypic heterogeneity, +1 more

5 terms

niemann-pick disease type c medical

"five children with Niemann-Pick disease type C (NPC) aged 12 to <24 months"

A rare inherited disorder in which cells cannot move cholesterol and other fats properly, causing them to build up like a clogged waste line and leading to progressive neurological problems, liver dysfunction, and variable symptoms that can appear from infancy to adulthood. It matters to investors because effective treatments are limited, so drug candidates can attract strong regulatory incentives, premium pricing and focused patient populations, but clinical development is small, risky and uncertain.

pharmacokinetics medical

"assessing safety, tolerability, and pharmacokinetics over up to 36 months"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

open-label medical

"This multicenter, open-label pediatric substudy evaluated arimoclomol"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

phenotypic heterogeneity medical

"Developmental assessments showed variable delays, reflecting underlying phenotypic heterogeneity."

Phenotypic heterogeneity is the presence of different observable traits, behaviors, or responses among cells, patients, or organisms even when they share similar genetic backgrounds or treatment conditions. For investors, it matters because this variability can make a drug, diagnostic, or treatment work well in some people but not others, increasing clinical trial risk, development costs, and market uncertainty—like identical recipes producing different cakes under varying ovens.

phase 2/3 medical

"Results from the phase 2/3 open-label pediatric substudy"

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed

BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced the publication of “Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy” in Molecular Genetics and Metabolism Reports. This multicenter, open-label pediatric substudy evaluated arimoclomol, in addition to concomitant miglustat, in five children with Niemann-Pick disease type C (NPC) aged 12 to <24 months at enrollment, assessing safety, tolerability, and pharmacokinetics over up to 36 months of treatment.

“The publication of these data adds to the growing body of clinical evidence supporting MIPLYFFA across age groups in NPC,” said Christine i Dali, Zevra’s Vice President, Clinical Science and an author of the publication. “Understanding the safety and pharmacokinetic profile of arimoclomol in these young children is critical as we continue to explore the potential role of earlier treatment initiation for patients living with this devastating disease.”

Arimoclomol was generally well tolerated, with no new safety signals, and pharmacokinetic results were consistent with older pediatric populations. Developmental assessments showed variable delays, reflecting underlying phenotypic heterogeneity. Although limited by small sample size, the study provides preliminary evidence supporting initiation of MIPLYFFA in this age group.

About MIPLYFFA^® (arimoclomol)

MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with more than 5 years of patient experience across more than 270 NPC patients worldwide through a Phase 2/3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.

INDICATIONS AND USAGE

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve.

Embryofetal Toxicity: MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.

Increased Creatinine without Affecting Glomerular Function: Across clinical trials of MIPLYFFA, mean increases in serum creatinine of 10% to 20% compared to baseline were reported. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function.

During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.

The most common adverse reactions in Trial 1 (≥15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.

Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients were hypersensitivity reactions including urticaria and angioedema.

To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. toll-free at 1-844-600-2237 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interaction(s): Arimoclomol is an inhibitor of the organic cationic transporter
2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.

Use in Females and Males of Reproductive Potential: Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.

Renal Impairment: The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥15 mL/minute to <50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.

MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.

For more information, please see the full Prescribing Information, including Instructions for Use

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the potential use of arimoclomol in infants with NPC. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com

FAQ

What did Zevra Therapeutics (ZVRA) announce about MIPLYFFA data on June 23, 2026?

Zevra announced positive MIPLYFFA data from a phase 2/3 pediatric substudy in infants with Niemann-Pick disease type C. According to Zevra, the open-label study showed arimoclomol was generally well tolerated with no new safety signals.

What were the key results of the MIPLYFFA pediatric substudy in NPC infants (ZVRA)?

The substudy found MIPLYFFA was generally well tolerated in five NPC infants aged 12–<24 months. According to Zevra, no new safety signals were observed and pharmacokinetic results were consistent with those seen in older pediatric populations.

How many infants with Niemann-Pick disease type C were included in Zevra's MIPLYFFA substudy?

The pediatric substudy enrolled five children with Niemann-Pick disease type C aged 12 to <24 months. According to Zevra, these patients received arimoclomol with concomitant miglustat and were followed for up to 36 months of treatment.

What does the new MIPLYFFA safety data mean for young NPC patients and ZVRA investors?

The data suggest MIPLYFFA has a consistent safety and pharmacokinetic profile in very young NPC patients. According to Zevra, findings provide preliminary evidence supporting treatment initiation in this age group, potentially broadening the therapy’s addressable patient population if further studies confirm benefits.

In what journal were the new MIPLYFFA infant NPC data from Zevra Therapeutics published?

The MIPLYFFA infant NPC substudy results were published in Molecular Genetics and Metabolism Reports. According to Zevra, the article, titled “Arimoclomol in infants with Niemann-Pick disease type C,” adds to the growing clinical evidence across age groups.

Did Zevra report any developmental outcomes in the MIPLYFFA infant NPC substudy?

Developmental assessments showed variable delays among enrolled infants with Niemann-Pick disease type C. According to Zevra, these differences were viewed as reflecting underlying phenotypic heterogeneity rather than new safety concerns, and the study remained focused primarily on safety and pharmacokinetics.